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Overcoming tumor resistance to cisplatin through
micelle-mediated combination chemotherapy†
Dongfang Zhou,a Yuwei Cong,a,b Yanxin Qi,a Shasha He,a,b Hejian Xiong,a,b
Yanjuan Wu,a,b Zhigang Xie,a Xuesi Chen,c Xiabin Jinga and Yubin Huang*a
The main obstacles to cancer therapy are the inability to target cancer cells and the acquired drug resist-
ance after a period of chemotherapy. Reduced drug uptake and DNA repair are the two main mechanisms
involved in cisplatin resistance. In the present investigation, canthaplatin, a Pt(IV) pro-drug of cisplatin and
a protein phosphatase 2A (PP2A) inhibitor (4-(3-carboxy-7-oxa-bicyclo[2.2.1]heptane-2-carbonyl)pipera-
zine-1-carboxylic acid tert-butyl ester), was designed and delivered using PEG-b-PLGA micelles for com-
bination chemotherapy. Polymer/canthaplatin micelles facilitated the delivery of the drug into cancer cells
through endocytosis and diminished DNA repair by PP2A inhibition, resulting in enhanced anti-tumor
eﬃciency and excellent reversal ability of tumor resistance to cisplatin both in vitro and in vivo. Addition-
ally, the polymer/canthaplatin micelles could prolong drug residence in the blood and decrease the side
eﬀects when compared to cisplatin.
Introduction
Major impediments for successful cancer therapy are drugs’
inability to target cancer cells and the side eﬀects on normal
cells. Most cancer therapies today are toxic to not only tumor
but also healthy tissues. And cancer patients often succumb to
treatment more than to the disease. Furthermore, generation
of drug resistance to external agents makes chemotherapy only
work for short periods. Platinum(II) compounds, cisplatin in
particular, are employed in 50%of all cancer therapies, although
accompanied by severe side eﬀects and acquired resistance.1–4
It is clear that a novel paradigm is necessary to produce a safer
and more eﬀective cancer therapy using platinum.
Cisplatin has been put on numerous laboratory trials to
minimize its side eﬀects and increase cancer cells’ suscepti-
bility to it.5,6 Several compounds such as mitaplatin and etha-
craplatin have been developed to combine Pt(IV) pro-drugs
with other chemotherapeutics for combination chemother-
apy.7,8 And some polymeric nano-carriers have also been
explored for Pt(IV) pro-drug delivery and combination
chemotherapy.9–16 Lippard co-encapsulated cisplatin and doce-
taxel in polymer nanoparticles with synergistic cytotoxicity
to prostate cancer cells.10 Mitaplatin was also encapsulated
in PEG–PLGA nanoparticles through a double emulsion
method.13 Daunorubicin was reported to be delivered with oxa-
liplatin in co-assembled nanomicelles.16 These systems
demonstrated Pt-based drugs’ potential attributes of improved
tolerance and eﬃcacy. However, it is still a challenge to over-
come acquired tumor resistance to cisplatin both in vitro and
in vivo.
Cisplatin sensitivity of cells correlates with DNA platination
in that DNA is the ultimate target of cisplatin.17 Tumor cells
can be cisplatin-resistant, namely they can achieve a reduction
in the level of DNA platination through several mechanisms
including reduced drug uptake, drug deactivation in cells,
apoptosis inhibition and DNA repair.18–21 Aiming at the two
main mechanisms of cisplatin resistance, reduced drug uptake
and DNA repair, we have previously reported a polymer–
(tandem drugs) conjugate system with enhanced cancer treat-
ment eﬃciency against malignant H22 tumors. In that system,
a protein phosphatase 2A (PP2A) inhibitor, demethylcanthari-
din (DMC), was combined with cisplatin to block DNA repair,
and polymeric carriers were further used to deliver higher level
drugs to cancer cells through endocytosis.22 However,
improved results against cisplatin-resistant cells and tumors
directly need to be demonstrated in vitro and in vivo to verify
our strategy. Recently, 4-(3-carboxy-7-oxa-bicyclo[2.2.1]heptane-
2-carbonyl)piperazine-1-carboxylic acid tert-butyl ester (LB),
a DMC derivative with less toxicity and more PP2A inhibition
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specificity, demonstrated an impressive eﬀect against a range
of cancers in combination with temozolomide or doxorubi-
cin.23,24 It is reasonable to suggest that LB could be an attrac-
tive sensitizer when combined with cisplatin to combat
cisplatin resistance.
Herein, we report a novel chemotherapeutic agent, cantha-
platin, appending LB to cisplatin in a Pt(IV) pro-drug form.
And canthaplatin was further encapsulated in PEG-b-PLGA
nano-micelles (polymer/canthaplatin micelles) for polymeric
combination chemotherapy. The drug-loaded micelles could
facilitate the delivery of canthaplatin into cancer cells through
endocytosis and diminish DNA repair by PP2A inhibition of
the intracellular reduced LB (Scheme 1). More importantly,
tumor resistance to cisplatin was circumvented by the use of
the polymer/canthaplatin micelles both in vitro and in vivo.
Materials and methods
Materials
Hydrogen peroxide (H2O2), N,N′-carbonyldiimidazole (CDI),
and BOC-piperazine were purchased from Sigma-Aldrich. Cis-
platin (purity 99.5%) was bought from Shandong Boyuan
Chemical Company, China, and DMC (purity 99%) was bought
from Nanjing Zelang Biomedical Company, China. PEG5k-
b-PLGA5k and all other chemicals were purchased from Sigma-
Aldrich and used as received.
General measurements
1H NMR spectra were measured by a Unity-300 MHz NMR
spectrometer (Bruker) at room temperature. Fourier transform
infrared (FTIR) spectra were recorded with a Bruker Vertex 70
spectrometer. Mass spectroscopy (ESI-MS) measurements
were performed using a Quattro Premier XE system (Waters)
equipped with an electrospray interface (ESI). Inductively
coupled plasma optical emission spectroscopy (ICP-OES; iCAP
6300, Thermo Scientific, USA) was used to determine the
total platinum contents in the micelles and samples obtained
outside of the dialysis bags in drug release experiments. Induc-
tively coupled plasma mass spectrometry (ICP-MS; Xseries II,
Thermo Scientific, USA) was used for quantitative determi-
nation of trace levels of platinum. Particle size and size distri-
bution of micelles were determined by DLS with a vertically
polarized He–Ne laser (DAWN EOS, Wyatt Technology, USA).
The morphology of the polymer/canthaplatin micelles was
measured by TEM performed with a JEOL JEM-1011 electron
microscope. Clinical parameters were measured by an auto-
matic biochemical analyzer (Mindray BS-220, China), and
white blood cell concentration (WBC) was measured by an
automatic blood counter system (ABX Micros 60, France).
Flow cytometry (BD Biosciences) was used to determine
whether treatment specifically induces apoptosis.
Preparation and characterization of polymer/canthaplatin
micelles
Synthesis of canthaplatin. LB and DMC-Pt-DMC were syn-
thesized according to previous reports.25,26 Canthaplatin was
synthesized as follows: briefly, CDI (170 mg, 1.05 mmol) in
dried DMF (16 mL) was added to a solution of DMC-Pt-DMC
(335 mg, 0.5 mmol) in dried DMF (8 mL), and the mixture was
heated to 60 °C. After 10 min of stirring, the solution was
cooled to room temperature and CO2 was removed by flushing
with argon. BOC-piperazine (195 mg, 1.05 mmol) in dried
DMF (4 mL) was added drop-wise to the above solution and
the mixture was left for 24 h at room temperature. DMF was
removed under reduced pressure and water (50 mL) was then
added, leaving a sticky white residue on the flask wall. The
light yellow aqueous solution was decanted and the residue
was washed with water. The residue was triturated in excess
diethyl ether, yielding canthaplatin as a white precipitate,
which was filtered, washed with excess diethyl ether
and recrystallised from THF–hexane (yield: 51.0%; 256.7 mg).
Canthaplatin was characterized using FTIR (Fig. S1†), 1H NMR
(Fig. S2†), ESI-MS (Fig. S3†), and elemental analysis
(Table S1†).
Preparation of polymer/canthaplatin micelles. Micelles were
prepared through a nano-precipitation process following a
published protocol.15 Briefly, 1 mg of PEG-b-PLGA and 1 mg of
canthaplatin dissolved in acetonitrile were added drop-wise
into deionized water under stirring. The resulting solution was
then stirred at room temperature for 2 h and washed with an
Amicon Ultra centrifugal filter (Millipore, Billerica, MA) with a
molecular weight cutoﬀ of 10 kDa, and then was freeze-dried.
The nano-micelle size was obtained from DLS. The
morphology and micelle size were further characterized using
TEM. Platinum content and drug loading eﬃciency of the
nanoparticles were determined by ICP-OES.
Scheme 1 (a) Synthesis of canthaplatin, (b) preparation of polymer/
canthaplatin micelles and (c) schematic representation of the intracellu-
lar action after endocytosis of polymer/canthaplatin micelles.
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Platinum release from polymer/canthaplatin micelles. 2 mg
of lyophilized polymer/canthaplatin micelles (Pt content:
11.4 wt%) was dissolved in 2 mL of buﬀered solution (100 mM
PBS, pH = 7.4). The solution was then placed into a pre-
swollen dialysis bag with a molecular weight cutoﬀ of 3 kDa
and immersed into 18 mL buﬀered solution. The dialysis was
conducted at 37 °C in a shaking culture incubator. 0.5 mL of
sample solution was withdrawn from the incubation medium
at specified time intervals and measured for Pt concentration
by ICP-OES. After sampling, an equal volume of fresh buﬀered
solution was immediately added into the incubation medium.
The platinum released from the micelles was expressed as the
percentage of cumulative platinum outside the dialysis bag
relative to the total platinum in the micelles.
In vitro studies
Cell culture. Lung carcinoma A549 cells and cisplatin-resist-
ant A549/DDP cells were purchased from the Institute of Bio-
chemistry and Cell Biology, Chinese Academy of Sciences,
Shanghai, China, and grown in DMEM (Life Technologies)
supplemented with 0.03% L-glutamine and 1% penicillin/
streptomycin in 5% CO2 at 37 °C. A549/DDP cells were main-
tained with 2 μg mL−1 of cisplatin. For MTT and other assays,
the resistant cells were cultured in cisplatin-free medium for
10 days before conducting cytotoxicity assays.
PP2A activity assay. 5 × 105 A549 cells were seeded into six-
well tissue culture plates and incubated overnight under stan-
dard growth conditions. The media for the cell lines were then
replaced by fresh growth media with and without cisplatin, LB,
canthaplatin and polymer/canthaplatin micelles with a Pt or
LB content of 5 μM. After 3 h (a duration suﬃcient for drug
uptake, but insuﬃcient for post-exposure modification or cell
death), cells were washed 3 times in a 0.9% normal saline solu-
tion. Tissue protein extraction reagent (T-PER; CWBiotec) solu-
tion was added to cells for protein extraction. Lysates from
each treatment group were assayed using a malachite green
phosphatase assay specific for serine/threonine phosphatase
activity (Ser/Thr phosphatase assay kit; Invitrogen). The relative
activity of PP2A was calculated according to the following
equation: PP2A activity = (mean experimental phosphate
amount/mean control phosphate amount) × 100 (%).
MTT assay. The cytotoxicity of drugs was evaluated by a
MTT assay following a published protocol.27 Cells were seeded
in 96-well plates at a density of 4 × 103 cells per well and incu-
bated in DMEM overnight. The medium was then replaced by
cisplatin, canthaplatin, polymer/canthaplatin micelles at a
final Pt concentration from 1.68 to 108 μM. The incubation
was continued for 48 h or 72 h. Then, MTT solution (20 μL) in
PBS (5 mg mL−1) was added and the plates were incubated for
another 4 h at 37 °C, followed by removal of the culture
medium containing MTT and addition DMSO (150 μL) to
each well to dissolve the formazan crystals formed. Finally, the
plates were shaken for 10 min, and the absorbance of forma-
zan product was measured at 490 nm by a microplate
reader. Treatment groups for each cell line were replicated
three times.
Annexin-V assay. 5 × 105 cells for each cell line (A549, A549/
DDP) were seeded into six-well tissue culture plates and incu-
bated overnight under standard growth conditions. The media
for the cell lines were then replaced by fresh growth media
with and without cisplatin, canthaplatin and polymer/cantha-
platin micelles with a Pt content of 10 μM. Treatment groups
for each cell line were replicated three times. Cells were then
incubated for 48 h at 37 °C and harvested with 0.25% trypsin–
EDTA. Cells were washed with PBS and subsequently stained
by annexin-V in accordance with the manufacturer’s protocol.
Flow cytometry was performed with a BD LSR II flow cytometer
(BD Biosciences) and data were analyzed using BD FACSDiva.
Cellular uptake. 5 × 105 cells for each cell line (A549, A549/
DDP) were seeded into six-well tissue culture plates and incu-
bated overnight under standard growth conditions. Then the
cells were treated with cisplatin, canthaplatin or polymer/
canthaplatin micelles with a Pt content of 50 μM for 6 h at
37 °C. To quantitatively determine Pt uptake by cells, the cell
samples were washed three times with ice-cold PBS to remove
surface-bound drugs first, and then lysed by adding 200 μL cell
lysis buﬀer (Beyotime Institute of Biotechnology, Shanghai,
China). 100 μL of the cell lysis solution for each sample was
used directly to measure the Pt content by ICP-MS. The other
100 μL of the cell lysis solution was used to determine the
protein content in each cell sample by using a bicinchoninic
acid protein assay kit (Beyotime Institute of Biotechnology,
Shanghai, China). The platinum content was expressed
as micrograms of Pt per milligram of total proteins. All experi-
ments were repeated three times.
Repair of DNA–Pt adduct. A549 cells and A549/DDP cells
were seeded in six-well tissue culture plates at a density of
5 × 105 cells per well and incubated in DMEM overnight. Cells
pre-treated with cisplatin, canthaplatin and polymer/cantha-
platin micelles with a Pt content of 50 μM for 6 h were washed
three times with ice-cold PBS and frozen at −80 °C (zero time
control) or re-incubated in drug-free medium for 1, 2, 4, 8 and
24 h to allow for DNA repair. After the repair incubations, cells
were washed twice with cold PBS and again frozen at −80 °C
until DNA was isolated and quantified using DNA extract
reagent (Qiagen). The total DNA-bound platinum was
estimated by ICP-MS. The platinum content was expressed as
nanograms of Pt per milligram of total DNA. Repair of DNA–Pt
adduct was calculated by comparing the platinum content
of the repair samples with that of the zero time control. All
experiments were repeated three times.
In vivo experiments
Animal use. Kunming (KM) mice (6–8 weeks old) and nude
BALB/c mice (4–6 weeks old) were purchased from Jilin Univer-
sity (Changchun, China). All mice were maintained under
required conditions (e.g., pathogen-free condition for nude
mice) and had free access to food and water throughout the
experiments. Use of them for this study was approved by the
Animal Ethics Committee of Changchun Institute of Applied
Chemistry, Chinese Academy of Sciences.
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In vivo anticancer eﬃcacy evaluation. A549 or A549/DDP
xenograft tumor models were implanted subcutaneously into
the right flank of nude BALB/c mice (1 × 107 A549 or A549/
DDP cells in 0.1 mL). Tumor nodules were allowed to grow to
a volume of ∼100 mm3 before initiating treatment. Tumor-
bearing BALB/c mice were randomly assigned to four groups:
(1) saline (n = 5), (2) cisplatin (4 mg kg−1) (n = 5), (3) canthapla-
tin (2.5 mg Pt kg−1) (n = 5), (4) polymer/canthaplatin micelles
(2.5 mg Pt kg−1) (n = 5), where n is the number of mice in each
group. Tumor length and width were measured with calipers,
and the tumor volume was calculated using the following
equation: tumor volume = length × width × width/2.
Prior to treatment, all the mice were numbered using ear
tags, and their weight and the initial tumor volume were
measured and recorded. Test animals received three intra-
venous injections on days 0, 4 and 7 and the injection volume
was 200 μL. The weight and tumor volume of each mouse were
measured every two days over a period of ∼30 days.
PP2A activity assay. PP2A activity was assayed in A549 xeno-
graft-bearing nude BALB/c mice. After a single intravenous
injection of 0.1 mL of canthaplatin or polymer/canthaplatin
micelles with a Pt content of 1 mg kg−1, the tumor tissues at
diﬀerent times (0 h, 2 h, 4 h, 8 h, 16 h, 24 h, and 3 mice for
each group) after injection were collected, and then tissue
protein extraction reagent solution was added for protein
extraction. Lysates from each treatment group were assayed for
PP2A activity.
Bio-distribution and excretion study. The blood persistence
properties of canthaplatin and polymer/canthaplatin micelles
were determined using tumor-bearing KM mice. The animals,
three per group, were injected in the tail vein with 0.1 mL of
canthaplatin and polymer/canthaplatin micelles with a Pt
content of 1 mg kg−1. At predetermined time intervals, blood
samples were collected in pre-weighed heparinized tubes. The
percentage of Pt was calculated by taking into consideration
that blood constitutes 7% of body weight. Major tissues
including heart, liver, spleen, lung, kidney and tumor were
also collected and washed with 0.9% saline before being
weighed. All the tissues were treated with concentrated nitric
acid on heating, to obtain clear solutions. The platinum con-
tents in the solutions were determined by ICP-MS and the con-
tents in each tissue were subsequently calculated.
Toxicity evaluation. KM mice were used to evaluate the
maximum tolerated dose (MTD) of cisplatin, canthaplatin, and
polymer/canthaplatin micelles. All groups (n = 3) received a
single dose by intravenous injection. Four groups of mice
received cisplatin at a dose of 1, 3, 5, 10 mg kg−1. Five groups
of mice received either canthaplatin or polymer/canthaplatin
micelles with a Pt content of 1, 3, 5, 10 and 15 mg kg−1. The
control groups received 10, 20, 40, 80, and 100 mg kg−1 of
empty polymer micelles. The injection volume was 0.2 mL in
all cases. The weight and physical states of all mice were moni-
tored for a period of 15 days.
After that a blood sample of each mouse was collected from
the retro-orbital plexus into a coagulation-promoting tube
(Shandong Nanyou Medical Appliance, China), and then
centrifuged at 3000 rpm for 5 min to obtain plasma samples
for measuring clinical parameters including urea nitrogen
(UREA), creatinine (CREA), uric acid (UA), alanine aminotrans-
ferase (ALT), and aspartate aminotransferase (AST) by an auto-
matic biochemical analyzer (Mindray BS-220, China), and
WBC by an automatic blood counter system (ABX Micros 60,
France).
Statistical analysis. The data were expressed as mean ± stan-
dard deviation (SD). Student’s t-test was used to determine the
statistical diﬀerence between various experimental and control
groups. Diﬀerences were considered statistically significant
at a level of p < 0.05.
Results and discussion
Synthesis and characterization of canthaplatin
An ordinary combination of cisplatin and LB has several
potential problems. The diﬀerent solubility of cisplatin and LB
in water makes it diﬃcult to obtain a homogenous injectable
solution. Even worse, the severe side eﬀects from cisplatin still
remain. Our tactic is to employ a novel inert platinum(IV) com-
pound by tethering LB to cisplatin (to give a new compound
named canthaplatin) (Scheme 1).
Direct acylation of cis,cis,trans-Pt(NH3)2Cl2(OH)2 with an
excess of LB chloride as a reported method failed to give
canthaplatin, because the Boc group of LB proved to be
unstable to the free HCl in the acylation system.28 Acylation of
cis,cis,trans-Pt(NH3)2Cl2(OH)2 using LB anhydride was also
unsuccessful. Alternatively, the synthesis of canthaplatin was
achieved via a two-step reaction process. Precursor DMC-Pt-
DMC was obtained by ring-opening reaction of DMC with
cis,cis,trans-Pt(NH3)2Cl2(OH)2,
26 which was further condensed
with BOC-piperazine subsequently to give canthaplatin. By
controlling and optimizing reaction conditions, the target
compound can be readily isolated in moderate yield when CDI
was used as the condensation agent. FTIR, ESI-MS, 1H NMR
and elemental analyses confirmed the structure of canthapla-
tin (Fig. S1–S3 and Table S1†). Cisplatin(II) and LB fragments
were detected by ESI-MS (Fig. S4†) under a mimicking cancer
cell environment (ascorbic acid concentration is 5–10 mM),29
which verified our hypothesis that canthaplatin could be
reduced to cisplatin(II) and LB in cancer cells to carry out its
dual killing mechanisms.
Preparation and drug release of polymer/canthaplatin micelles
Pt(II) complexes are typically kinetically labile. An impetus for
investigating Pt(IV) pro-drugs is their more prominent kinetic
inertness.30 This reduced reactivity is expected to translate into
sustained circulation in vivo during which the masked Pt(II)
pharmacophore remains safe from deactivation by biological
nucleophiles. Only upon entering the reducing environment of
a cancer cell is the complex supposed to be reduced, releasing
the active Pt(II) agent.31 We propose that nanomicelle encapsu-
lation provides the guest platinum complex an additional
degree of protection from reductants and nucleophiles by
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physically preventing interaction between these agents and the
encapsulated platinum complex.
The interior of the nanoparticles is more hydrophobic than
their surface. Synthesis of Pt(IV)-encapsulated nanoparticles
requires that the Pt(IV) guest be suﬃciently soluble in organic
solvents like acetonitrile and DMF. Canthaplatin dissolves in
acetonitrile (10 mg mL−1), making it a suitable candidate for
encapsulation. Polymer/canthaplatin micelles were prepared
by nano-precipitation. TEM and DLS were used to characterize
the morphology and size of the micelles. Platinum content was
determined by ICP-MS to be 11.4 wt%. The average loading
eﬃciency was 20%. Results showed that the micelles assumed
a spherical shape, the mean diameters were about 70 nm
determined by TEM or 82 nm determined by DLS, and no
aggregation was observed (Fig. 1a).
Polymer/canthaplatin micelles are actually pro-drugs of cis-
platin(II) and LB. Only when canthaplatin escapes from the
micelles and is reduced to bioactive fragments can it act as an
antitumor agent. Since canthaplatin is physically dispersed
throughout the hydrophobic core of the PEG-b-PLGA micelles,
the release of canthaplatin should be a slow, diﬀusion-con-
trolled process. We studied platinum release by dialysis with
the polymer/canthaplatin micelles against PBS at pH 7.4 to
mimic physiological conditions. The amount of platinum
released from the micelles was measured by ICP-OES and is
shown in Fig. 1b. An initial burst release during the first 1 h
represents nearly 20% of the total platinum. Thereafter, a
period of controlled platinum release occurs, reaching a value
of 80% after 48 h. The sustained release behavior confirmed
that canthaplatin is a suitable candidate for building a drug-
loaded nanoparticle.
The release of LB was indirectly evaluated with a PP2A
activity assay. As shown in Fig. 2, it was found that the PP2A
activity level in A549 cells exposed to LB for 3 h decreased to
37.8% of the control level, while the level of those exposed to
canthaplatin and polymer/canthaplatin micelles decreased to
48.5% and 67.3%, respectively. Also, in vivo, canthaplatin
induced 41.6% inhibition of PP2A activity of A549 tumor
tissues after 16 h, whereas polymer/canthaplatin micelles
exhibited sustained inhibition of PP2A to 44.4% of control
level even after 24 h. The reduced PP2A activity level clearly
proved that canthaplatin and LB molecules could be controlla-
bly released from the polymer/canthaplatin micelles and still
possess the capability to inhibit PP2A function.
Fig. 1 (a) TEM morphology (scale bar = 500 nm) and DLS characterization (inset) of polymer/canthaplatin micelles. (b) Platinum release proﬁle of
polymer/canthaplatin micelles in PBS solution (pH = 7.4).
Fig. 2 PP2A activity in (a) A549 cells after 3 h incubation of drugs and (b) A549 xenograft-bearing BALB/c mice at diﬀerent times after i.v. injection
of drugs (1 mg Pt kg−1). Data are expressed as mean ± standard deviation (n = 3).
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Eﬀect of polymer/canthaplatin micelles on cisplatin resistance
in vitro
As mentioned above, reduced drug uptake and DNA repair are
the two main mechanisms of cisplatin resistance. Previous
reports have demonstrated that polymeric nano-carriers would
have the chance to improve intracellular drug delivery.32 And
suppression of PP2A activity would have an inhibitory eﬀect on
DNA repair, since PP2A is a ubiquitously expressed protein
essential for nucleotide excision repair and DNA damage-
induced defense mechanism.33,34 Fortunately, the character-
istics of PP2A inhibition and polymer encapsulation which
were associated with canthaplatin provided us an excellent
opportunity and a platform to promote deeper investigation of
anticancer eﬃcacy especially in cisplatin-resistant cancer cells.
The cytotoxicity of cisplatin, canthaplatin and polymer/cantha-
platin micelles was assayed using A549 lung cancer cells and
A549/DDP cisplatin-resistant cells (Table 1, Table S3†). A549/
DDP cells clearly showed resistance to cisplatin: the IC50 value
of cisplatin in A549/DDP cells (61.2 μM) was much higher than
that in A549 cells (3.6 μM) at 72 h, representing a resistant
factor (RF) of 17 (Table 1 and Fig. 3a). As expected, canthapla-
tin itself was more susceptive than cisplatin in A549/DDP cells
(31.9 μM), and the RF was significantly reduced (RF = 2.2)
(Fig. 3b). It was exciting to find that the cytotoxicity of the
polymer/canthaplatin micelles was the highest in A549/DDP
cells at 72 h, and the RF was further reduced to 1.4 (Fig. 3c).
These results suggested that canthaplatin may overcome
acquired resistance to cisplatin to some extent, and polymer
encapsulation could further enhance this ability. An annexin-V
assay was performed to further determine the percentage of
apoptotic cells after exposure to cisplatin, canthaplatin, or
polymer/canthaplatin micelles in A549 cells and A549/DDP
cells (Fig. 4). Cisplatin induced severe apoptosis in A549 cells
(65.3%), but a low level of apoptosis in A549/DDP cells (9.0%).
On the contrary, polymer/canthaplatin micelles could induce
more A549/DDP cell apoptosis (48.9%) compared to canthapla-
tin (14.4%) and cisplatin, showing good accordance with the
MTT results. All these data suggested that polymer/canthapla-
tin micelles possess excellent capacity to overcome cisplatin
resistance.
The enhanced anticancer activity of polymer/canthaplatin
micelles is believed to be a result of the polymeric decoration
and dual action modes of canthaplatin. Therefore, cellular
platinum uptake assay was performed firstly to compare the
drug amounts internalized by cells. The results are shown in
Table 1. It was found that after 6 h cisplatin incubation, the Pt
taken up by both A549 and A549/DDP cells was at low levels.
And the Pt taken up by A549/DDP cells (43.98 μg Pt mg−1
protein) was much less than that by A549 cells (94.05 μg Pt
mg−1 protein), implying the cisplatin-resistant character of
A549/DDP cells. Compared to cisplatin, increased cellular drug
uptake was found in both A549 cells (249.91 μg Pt mg−1
protein) and A549/DDP cells (281.6 μg Pt mg−1 protein) in the
canthaplatin group which may be attributable to its lipophilic
eﬃciency. It is noteworthy that after polymeric decoration of
canthaplatin, the Pt taken up from polymer/canthaplatin
micelles in A549 and A549/DDP cells was significantly
increased to 678.74 and 732.17 μg Pt mg−1 protein, respecti-
vely. All these results indicated that polymeric decoration of
canthaplatin led to enhanced drug accumulation in cancer
cells, providing a physical foundation for cisplatin resistance
Table 1 Representative IC50 values and Pt uptake of cisplatin, canthaplatin and polymer/canthaplatin micelles
Drugs
IC50 (μM of Pt) Pt uptake (μg Pt mg−1 protein)
A549 A549/DDP A549 A549/DDP
48 h 72 h 48 h 72 h 6 h
Cisplatin 6.3 ± 1.0 3.6 ± 0.6 87.3 ± 4.9 61.2 ± 3.7 94.05 ± 3.4 43.98 ± 2.9
Canthaplatin 26.4 ± 4.2 14.4 ± 3.3 51.8 ± 4.0 31.9 ± 2.5 249.91 ± 1.5 281.6 ± 2.7
Polymer/canthaplatin 22.7 ± 2.8 12.1 ± 3.7 36.2 ± 3.6 17.4 ± 3.0 678.74 ± 4.1 732.17 ± 3.5
Fig. 3 Cell viability curves of (a) cisplatin, (b) canthaplatin and (c) polymer/canthaplatin micelles against A549 and A549/DDP cells for 72 h.
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reversal. It is reasonable to suggest that nanoparticles may
re-activate the defective endocytosis and avoid the reduced
uptake caused by the low expression of copper transport
protein Ctr1 in resistant cells, to achieve the enhanced drug
accumulation.35–37
Cisplatin attacks nuclear DNA, leading to DNA damage
by intra-strand cross-links (DNA–Pt adducts). And repair of
damaged DNA, like removal of DNA–Pt adducts, is the main
mechanism of tumor resistance to cisplatin. Since PP2A is
essential for nucleotide excision repair which is the main DNA
repair mechanism in cisplatin-resistant cells, the eﬀects of
PP2A inhibition on DNA repair were also determined to
further understand the cell mechanism of cisplatin resistance
reversal induced by polymer/canthaplatin micelles. In the DNA
repair assays (Fig. 5), after 6 h pre-incubation of drugs with
cancer cells to form DNA–Pt adducts (Table S2†), 18.2% and
45.5% of the adducts were removed within the first 2 h in A549
and A549/DDP cells for cisplatin treatment, and the removal
amounts of DNA–Pt adducts after 24 h were further increased
to 45.1% and 81.6%, respectively. However, there was no sig-
nificant diﬀerence in the rate of removal for canthaplatin and
polymer/canthaplatin micelles, showing improved sensitivity
of these drugs to cisplatin-resistant cells (A549/DDP). Even
compared with small anti-resistance drug canthaplatin, the
DNA–Pt adduct removal of the polymer/canthaplatin micelles
group in A549/DDP cells within 24 h was much reduced to less
than 20%. These results clearly indicated that polymer/cantha-
platin micelles have a satisfactory character of diminishing
DNA repair by PP2A inhibition and overcoming cisplatin
resistance.
In vivo evaluation of cisplatin resistance of polymer/
canthaplatin micelles
To further prove the ability of the drug to overcome cisplatin
resistance, we evaluated the antitumor activity of polymer/
canthaplatin micelles in vivo against subcutaneous A549 and
A549/DDP tumors developed by injection of tumor cells in the
flank of BALB/c nude mice. The following regimens were admi-
nistered by intravenous drug injection three times in one
week: (i) saline, (ii) cisplatin (4 mg kg−1), (iii) canthaplatin
(2.5 mg Pt kg−1), and (iv) polymer/canthaplatin micelles
(2.5 mg Pt kg−1). We aimed to determine whether delivery
Fig. 4 Apoptosis induced against A549 and A549/DDP cells by canthaplatin, cisplatin and polymer/canthaplatin after 48 h incubation using an
annexin-V assay.
Fig. 5 DNA–Pt adduct repair with time in A549 and A549/DDP cells after 6 h pre-incubation (time = 0 h) of (a) cisplatin, (b) canthaplatin and (c)
polymer/canthaplatin micelles.
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of the pro-drug, canthaplatin with polymeric nanomicelles,
will result in enhanced antitumor eﬃcacy in vivo when com-
pared to free cisplatin given in its conventional dosage form.
The results showed that administration of cisplatin exhibited
good eﬃciency in restricting A549 tumors (Fig. 6a), but failed
to inhibit the growth of A549/DDP tumors and in consequence
the tumor volume increased to about 500 mm3 after 4 weeks
(Fig. 6c), which verified the tumor resistance to cisplatin of the
A549/DDP model. Interestingly, administration of canthaplatin
exhibited a lower eﬃciency than cisplatin for A549 tumors but
a better eﬃciency for A549/DDP tumors, corresponding to
the in vitro results. As expected, polymer/canthaplatin micelles
exhibited high antitumor activity in both tumor xenograft
models. Especially in the A549/DDP tumor model, polymer/
canthaplatin micelles successfully overcame the cisplatin
resistance of A549/DDP cells with substantially restricted
tumor growth, and the tumor size decreased to about 30 mm3
after 4 weeks. The present technology diﬀers in two distinct
ways, which in combination may explain our observed
improvement in drug therapeutic index. Foremost, we deli-
vered the two synergetic drugs, cisplatin and LB, in the form
of a Pt(IV) pro-drug which is more susceptive than cisplatin
to cisplatin-resistant tumors. In addition, we employed a
polymeric delivery vehicle, which we and others have shown to
improve drug eﬃcacy.9–16,22,38–41
Body weight was also monitored to evaluate the in vivo toxi-
city of the drugs. Administration of free cisplatin led to sig-
nificant body weight loss in both A549 and A549/DDP mice
during the first 10 days, while administration of canthaplatin
and polymer/canthaplatin micelles showed little eﬀect on body
weight growth of mice, indicating a reduced toxicity of the pro-
drug and drug system (Fig. 6b and d). We also found that poly-
meric encapsulation of canthaplatin resulted in a significant
prolongation of Pt presence in blood (Fig. S5†), and reduced
accumulation of Pt in liver and kidney while there was an
increased accumulation in tumors through the EPR eﬀect,
indicating the reduced nephrotoxicity and hepatotoxicity after
administration of polymer/canthaplatin micelles (Fig. S6†).
The in vivo toxicity was further evaluated by examining the
MTD and alterations of clinical chemistry parameters in KM
mice after treatment with polymer/canthaplatin micelles,
canthaplatin and cisplatin. MTD was estimated based on the
threshold at which dose all animals survived (Table S3†). From
the results, we conclude that MTD for polymer/canthaplatin
micelles is 10 mg Pt kg−1, and that for cisplatin is 5 mg kg−1
and canthaplatin is 5 mg Pt kg−1. Polymer/canthaplatin
micelles appeared to be better tolerated than cisplatin in its
conventional dosage form. As shown in Fig. 7, the level of
clinical chemistry parameters including UA, UREA, CREA, AST
and ALT were increased for groups treated with cisplatin at a
dose of 5 mg kg−1, indicating the appearances of severe renal
toxicity and hepatotoxicity. However, these toxicities were sig-
nificantly reduced in treatment with high doses of polymer/
canthaplatin micelles, showing clear advantage in safety. No
significant diﬀerences were observed between the groups
treated with canthaplatin and polymer/canthaplatin micelles.
Meanwhile, the analysis of WBC showed that treatment with
polymer/canthaplatin micelles led to minimal decrease in
WBC, indicating the lowest eﬀect on immune systems after
chemotherapy. These results revealed significant diﬀerential
Fig. 6 Tumor growth inhibition curves (a, c) and body weight change proﬁles (b, d) of female BALB/c nude mice bearing A549 xenografts (a, b) and
A549/DDP xenografts (c, d) after saline, cisplatin (4 mg kg−1), canthaplatin (2.5 mg Pt kg−1) and polymer/canthaplatin micelles (2.5 mg Pt kg−1) intra-
venous injection on days 0, 3, and 7. Data are expressed as mean ± standard deviation, n = 5, *p < 0.05.
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toxicity profiles for polymer/canthaplatin micelles and cispla-
tin as well as the beneficial eﬀects of polymeric micelles in
reducing commonly encountered toxicities.
Conclusions
In the present investigation, a Pt(IV) pro-drug of cisplatin and a
PP2A inhibitor (LB), canthaplatin, was designed and delivered
using PEG-b-PLGA micelles for combination chemotherapy.
Polymer/canthaplatin micelles facilitated the delivery of drugs
into cancer cells through endocytosis and diminished DNA
repair by PP2A inhibition, resulting in enhanced antitumor
eﬃciency and excellent reversal ability of tumor resistance to
cisplatin both in vitro and in vivo. Additionally, polymer/
canthaplatin micelles could prolong drug residence in blood
and decrease the side eﬀects when compared to cisplatin. Our
studies show it is possible to avoid the drug resistance and
side eﬀects that aﬀect the use of cisplatin in vivo, and would
have broad implications for cancer therapy given the relatively
ubiquitous use of cisplatin in oncology. We also suggest that
similar strategies could be undertaken to combine Pt(IV) pro-
drugs with polymeric co-delivery systems to synergistically
improve eﬃcacy and safety.
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